HUMA's 30 day historical volatility is 143.32%, in the 97th percentile of readings over the past year. This is a high percentile, meaning Humacyte Inc shares have swung far more than usual. HUMA's 30 day implied volatility sits at 79.56%, with an IV Rank of 2.38%, leaving IV 63.76 points below historical volatility. This means options are pricing in less movement than the stock has actually delivered, as of Nov 12, 2026.

Tracking HUMA historical volatility helps you see how much Humacyte Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, HUMA's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor HUMA 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. HUMA's 30 day historical volatility, or HUMA HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing HUMA's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes.

Humacyte Inc

Humacyte Inc (HUMA) Historical Volatility

Historical Volatility